Chair of the University of Pittsburgh Department of Immunology joins Single Cell Technology’s Scientific Advisory Board
2 June 2016
San Jose, CA April 28, 2016
Single Cell Technology, Inc. (SCT) today announced the appointment of Mark J. Shlomchik, M.D., Ph.D. to its Scientific Advisory Board. Dr. Shlomchik currently surves as the Chair of the Department of Immunology, School of Medicine, University of Pittsburgh. Dr. Shlomchik received his medical and doctoral degrees from the University of Pennsylvania, where he also completed residency training in pathology and laboratory medicine. After postdoctoral work at Fox Chase Cancer Center in Philadelphia, he joined the faculty at Yale University, rising to the rank of full professor in 2004. In 2013 Dr. Shlomchik was selected to head the University of Pittsburgh School of Medicine’s Department of Immunology.
In the area of lupus, Dr. Shlomchik’s work was among the first to elucidate the roles of B lymphocytes and Toll-like receptors in promoting disease. Both of these are now targets of drugs that are either approved or in development to treat autoimmune disorders in patients. In October 2012, Dr. Shlomchik’s team showed in Science Translational Medicine that an enzyme complex called NADPH oxidase, or NOX2, which plays an important role in the body’s resistance to bacteria and fungi, is also necessary to curb genetic predisposition to lupus. In addition to autoimmunity, B-cell immune responses and how vaccines elicit protective antibodies, Dr. Shlomchik has worked on bone marrow transplantation, where some of his findings have also resulted in an ongoing clinical trial.
Dr. Shlomchik’s current lab is interested in systemic autoimmune diseases, long-lived B cell immunity, and in immunopathogenesis, using transgenic and knockout mouse models to address questions of how autoreactive B cells arise and what are the role(s) that these cells play in mediating autoimmune disease.
Dr. Chun-Nan Chen, Founder and CEO of SCT said: “We reached out to Professor Shlomchik in the early stages of the company and because of his contribution we were able to develop a unique and powerful assay to identify high commercial value antibodies. Professor Shlomchik is a recognized authority on antibody discovery. His assessment and encouragement helped SCT to realize the promise of our patented technology. We feel privileged to have Professor Shlomchik join our SAB.”
ABOUT SINGLE CELL TECHNOLOGY, INC.
Single Cell Technology, Inc. (SCT) has pioneered a new approach to antibody discovery. Antibodies from secreting cells are rapidly screened against multiple molecules to measure their affinity and specificity and correctly paired mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS). In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. SCT integrates advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.